Barclays PLC Nurix Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 128,344 shares of NRIX stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,344

Previous 128,344 -0.0%

Holding current value

$2.8 Million

Previous $2.88 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$18.93 - $25.69 $1.06 Million - $1.44 Million	56,190 Added 77.88%	128,344 $2.88 Million
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $296,160 - $524,810	24,639 Added 51.86%	72,154 $1.51 Million
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $164,910 - $332,367	-21,224 Reduced 30.88%	47,515 $698,000
Q4 2023 Feb 15, 2024	BUY	$4.25 - $10.71 $5,406 - $13,623	1,272 Added 1.89%	68,739 $709,000
Q3 2023 Nov 07, 2023	SELL	$7.86 - $10.08 $11,978 - $15,361	-1,524 Reduced 2.21%	67,467 $530,000
Q2 2023 Aug 03, 2023	SELL	$8.7 - $13.28 $27,457 - $41,911	-3,156 Reduced 4.37%	68,991 $690,000
Q1 2023 May 04, 2023	SELL	$8.56 - $13.26 $235,485 - $364,782	-27,510 Reduced 27.6%	72,147 $642,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $149,536 - $221,271	15,166 Added 17.95%	99,657 $1.09 Million
Q3 2022 Nov 03, 2022	BUY	$12.33 - $19.81 $1.01 Million - $1.62 Million	81,760 Added 2993.78%	84,491 $1.1 Million
Q2 2022 Aug 12, 2022	SELL	$7.88 - $14.82 $19,290 - $36,279	-2,448 Reduced 47.27%	2,731 $34,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $67,016 - $153,557	5,179 New	5,179 $72,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account